GO:0032912 negative regulation of transforming growth factor beta2 production: Regulation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032912 describes any biological process that stops, prevents, or reduces the production of transforming growth factor-beta2 (TGF-beta2).
• TGF-beta2 is a secreted cytokine whose overproduction drives fibrosis, extracellular matrix deposition, and tumor progression in multiple tissues.
• Negative regulation of TGF-beta2 production is achieved through transcriptional repression, post-transcriptional miRNA targeting, and feedback loops involving matrix proteins.
• Dysregulated TGF-beta2 production is implicated in trabecular meshwork dysfunction, triple-negative breast cancer, corneal fibrosis, and anterior subcapsular cataract.
• Key experimental models include CRISPR knockout of TGFB2 or its regulators, point mutations in SMAD4, and overexpression of negative regulators such as miR-483-3p.
• Studying this process requires integrated methods: RNA-seq, proteomics, ELISA for secreted TGF-beta2, and functional assays in disease-relevant cell types.
Description
Transforming growth factor-beta2 (TGF-beta2) is a member of the TGF-beta superfamily of secreted cytokines that regulate cell proliferation, differentiation, extracellular matrix production, and immune responses. The Gene Ontology term GO:0032912, negative regulation of transforming growth factor beta2 production, captures any process that stops, prevents, or reduces the frequency, rate, or extent of TGF-beta2 production. This term is distinct from regulation of TGF-beta2 activity or signaling; it specifically concerns the biosynthesis and secretion of the TGF-beta2 ligand itself. Researchers study this process because excessive TGF-beta2 production is a hallmark of fibrotic diseases, cancer progression, and ocular pathologies. Understanding how cells negatively regulate TGF-beta2 production can reveal therapeutic targets for diseases where TGF-beta2 drives pathology.
negative regulation of transforming growth factor beta2 production At A Glance
| GO ID | GO:0032912 |
|---|---|
| GO term | negative regulation of transforming growth factor beta2 production |
| Ontology | biological_process |
| Synonym | down regulation of transforming growth factor-beta2 production; inhibition of transforming growth factor-beta2 production; negative regulation of TGFB2 production |
| Major function | Reduces the synthesis or secretion of TGF-beta2, thereby limiting its downstream fibrotic and oncogenic effects |
| Related genes | TGFB2, SMAD4, MIR483, ARG1, CD69, IL10 |
| Disease relevance | Fibrosis, triple-negative breast cancer, cataract, trabecular meshwork dysfunction, asthma |
| Research methods | CRISPR knockout, miRNA overexpression, RNA-seq, proteomics, ELISA |
What Is GO:0032912?
GO:0032912 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of production of transforming growth factor-beta2. It encompasses transcriptional, post-transcriptional, and feedback mechanisms that lower the amount of TGF-beta2 protein secreted or synthesized by a cell. This term is a child of negative regulation of transforming growth factor beta production and is specific to the TGF-beta2 isoform.
Why Is negative regulation of transforming growth factor beta2 production Important in Cell Biology?
Negative regulation of TGF-beta2 production is critical because TGF-beta2 is a potent driver of extracellular matrix deposition, epithelial-to-mesenchymal transition, and immune suppression. When this negative regulation fails, elevated TGF-beta2 contributes to fibrosis in the cornea, lens, and trabecular meshwork, as well as to aggressive cancer phenotypes. Conversely, enhancing negative regulation could be therapeutic. Thus, understanding the molecular players that suppress TGF-beta2 production provides a rational basis for drug target discovery and for interpreting disease-associated genetic variants.
• TGF-beta2 overproduction is a key mechanism in corneal fibrosis and scarring.
• In triple-negative breast cancer, a SRC-slug-TGF-beta2 axis drives poor clinical outcomes.
• miR-483-3p negatively regulates TGF-beta2/SMAD4 signaling in trabecular meshwork cells, linking this GO term to glaucoma-relevant biology.
• Arginase-1 promotes lens epithelial-to-mesenchymal transition, a process involving TGF-beta2 regulation.
• CD69 downregulates autoimmune reactivity through active TGF-beta production, highlighting immune regulation.
• Interleukin-10 and TGF-beta promoter polymorphisms are associated with allergies and asthma.
• Colorectal carcinoma cells produce TGF-beta that decreases endothelial VEGFR2 expression, affecting angiogenesis.
• TGF-beta negatively regulates collagen genes in hypertensive rat smooth muscle, showing context-dependent effects.
• Targeting negative regulators of TGF-beta2 production may offer therapeutic strategies for fibrosis and cancer.
What Happens During negative regulation of transforming growth factor beta2 production?
Transcriptional repression of TGFB2
In simple terms: The cell reduces the reading of the TGFB2 gene into messenger RNA.
Negative regulation of TGF-beta2 production can occur at the transcriptional level, where transcription factors or repressors bind to the TGFB2 promoter and reduce its activity. For example, in corneal fibroblasts, collagen type IV acts as a negative feedback modulator of TGF-beta, reducing its production. This feedback loop helps maintain tissue homeostasis and prevents excessive fibrosis.
Post-transcriptional regulation by microRNAs
In simple terms: Small RNA molecules called microRNAs can bind to TGFB2 mRNA and prevent it from being translated into protein.
MicroRNAs such as miR-483-3p have been shown to regulate extracellular matrix proteins via TGF-beta2/SMAD4 signaling in human trabecular meshwork cells. By targeting components of the TGF-beta2 pathway, miR-483-3p reduces TGF-beta2 production and downstream signaling, demonstrating a post-transcriptional mechanism for negative regulation.
Feedback inhibition by downstream effectors
In simple terms: Proteins produced as a result of TGF-beta2 signaling can turn around and shut down further TGF-beta2 production.
Negative feedback loops are common in TGF-beta signaling. For instance, collagen type IV, whose production is stimulated by TGF-beta, can subsequently inhibit TGF-beta production in corneal fibroblasts. This type of feedback ensures that TGF-beta2 levels are self-limiting and prevents runaway fibrosis.
Regulation by immune and inflammatory mediators
In simple terms: Immune signals can instruct cells to make less TGF-beta2.
Cytokines such as interleukin-10 (IL-10) can modulate TGF-beta production. Polymorphisms in the IL10 and TGFB1 promoters have been associated with allergies and asthma, suggesting that immune mediators influence TGF-beta regulation. Additionally, CD69, an activation marker on immune cells, downregulates autoimmune reactivity through active TGF-beta production, indicating a complex interplay between immune regulation and TGF-beta2 production.
Cross-talk with oncogenic signaling
In simple terms: Cancer-related signaling pathways can alter how much TGF-beta2 is produced.
In triple-negative breast cancer, a SRC-slug-TGF-beta2 signaling axis drives poor outcomes. This axis involves SRC kinase and the transcription factor slug (SNAI2) promoting TGF-beta2 production. Negative regulation of TGF-beta2 production in this context could be achieved by inhibiting SRC or slug, thereby reducing TGF-beta2 levels and potentially improving outcomes.
Key Genes Involved in GO:0032912 negative regulation of transforming growth factor beta2 production
The following genes and proteins are experimentally implicated in the negative regulation of TGF-beta2 production or in related TGF-beta2 biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TGFB2 | Encodes transforming growth factor beta2 | Target for knockout or knockdown to study production regulation |
| SMAD4 | Mediates TGF-beta signaling; regulated by miR-483-3p | Point mutations can alter TGF-beta2 signaling |
| MIR483 | MicroRNA that targets TGF-beta2/SMAD4 pathway | Overexpression reduces TGF-beta2 production |
| ARG1 | Arginase-1 promotes lens EMT involving TGF-beta2 | Knockout may reduce TGF-beta2-driven cataract |
| CD69 | Immune activation marker that downregulates autoimmune reactivity via TGF-beta | Knockout models show altered TGF-beta production |
| IL10 | Anti-inflammatory cytokine; promoter polymorphisms linked to asthma | Overexpression may modulate TGF-beta2 production |
| COL4A1 | Collagen type IV negative feedback modulator of TGF-beta | Knockdown may increase TGF-beta2 production |
| SRC | Kinase in SRC-slug-TGF-beta2 axis in TNBC | Inhibitors reduce TGF-beta2 production |
| SNAI2 | Slug transcription factor promoting TGF-beta2 | Knockout reduces TGF-beta2 in cancer models |
| VEGFR2 | Endothelial receptor downregulated by TGF-beta | TGF-beta production affects angiogenesis |
| TGFB1 | Related isoform; polymorphisms in asthma | Comparative studies with TGFB2 |
| COL1A1 | Collagen gene negatively regulated by TGF-beta in hypertension | Model for TGF-beta feedback |
| ACTA2 | Smooth muscle actin; marker of EMT | Readout of TGF-beta2 activity |
| CDH1 | E-cadherin; loss during EMT | Marker of TGF-beta2-driven EMT |
| FN1 | Fibronectin; ECM protein induced by TGF-beta2 | Readout of TGF-beta2 production |
| MMP2 | Matrix metalloproteinase; regulated by TGF-beta | Downstream effector |
| SERPINE1 | PAI-1; TGF-beta target gene | Readout of TGF-beta2 signaling |
| LTBP1 | Latent TGF-beta binding protein | Regulates TGF-beta2 secretion |
How Is negative regulation of transforming growth factor beta2 production Regulated?
The negative regulation of TGF-beta2 production is itself regulated at multiple levels. Transcriptional repressors, microRNAs such as miR-483-3p, and feedback loops involving extracellular matrix proteins like collagen type IV can all reduce TGF-beta2 production. In cancer, oncogenic signaling through SRC and slug can override negative regulation, leading to increased TGF-beta2. In immune contexts, CD69 and IL-10 can modulate TGF-beta production. Thus, the process is integrated with broader cellular signaling networks.
negative regulation of transforming growth factor beta2 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFB2 | Triple-negative breast cancer | CRISPR knockout in TNBC cell lines |
| MIR483 | Trabecular meshwork dysfunction / glaucoma | Overexpression in human trabecular meshwork cells |
| ARG1 | Anterior subcapsular cataract | Knockout in lens epithelial cells |
| COL4A1 | Corneal fibrosis | Knockdown in corneal fibroblasts |
| IL10 | Asthma and allergies | Promoter polymorphism knock-in in mice |
Fibrotic diseases of the eye
In corneal fibroblasts, collagen type IV provides negative feedback modulation of TGF-beta, and disruption of this feedback can lead to fibrosis. In the trabecular meshwork, miR-483-3p regulates extracellular matrix proteins via TGF-beta2/SMAD4 signaling, and its dysregulation may contribute to glaucoma. In anterior subcapsular cataract, arginase-1 promotes lens epithelial-to-mesenchymal transition, a process involving TGF-beta2.
Triple-negative breast cancer
A SRC-slug-TGF-beta2 signaling axis drives poor outcomes in triple-negative breast cancers. Negative regulation of TGF-beta2 production is subverted in these tumors, leading to increased TGF-beta2 that promotes invasion and immune evasion. Targeting this axis could restore negative regulation and improve patient outcomes.
Immune and allergic disorders
CD69 downregulates autoimmune reactivity through active TGF-beta production, indicating that negative regulation of TGF-beta2 is important for preventing autoimmunity. Polymorphisms in the IL10 and TGFB1 promoters are associated with allergies and asthma, suggesting that genetic variation in TGF-beta regulation contributes to these conditions.
Hypertension and vascular remodeling
In hypertensive rats, TGF-beta and receptor tyrosine kinase-activating growth factors negatively regulate collagen genes in smooth muscle. This highlights the role of TGF-beta in vascular remodeling and the importance of its negative regulation in cardiovascular disease.
From negative regulation of transforming growth factor beta2 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of TGFB2 reduce fibrosis? | TGFB2 knockout mice or CRISPR knockout in fibroblasts |
| Does miR-483-3p overexpression reduce TGF-beta2 production? | Lentiviral overexpression in trabecular meshwork cells |
| Does point mutation in SMAD4 alter TGF-beta2 signaling? | CRISPR knock-in of SMAD4 mutations in cancer cell lines |
| Does SRC inhibition reduce TGF-beta2 in TNBC? | CRISPR knockout of SRC or pharmacological inhibitors |
| Does ARG1 knockout prevent lens EMT? | CRISPR knockout in lens epithelial cells |
| Does CD69 modulate TGF-beta production? | CD69 knockout mice |
How to Study the negative regulation of transforming growth factor beta2 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | mRNA levels of TGFB2 and related genes | Transcriptional regulation studies |
| ELISA | Secreted TGF-beta2 protein concentration | Quantifying production changes |
| Western blot | Protein levels of TGF-beta2 and signaling intermediates | Validating knockdown or overexpression |
| CRISPR knockout | Loss-of-function of candidate genes | Identifying negative regulators |
| miRNA overexpression | Effect of microRNAs on TGF-beta2 | Studying post-transcriptional regulation |
| Immunofluorescence | Localization of TGF-beta2 and EMT markers | Tissue-level analysis |
| Luciferase reporter | Promoter activity of TGFB2 | Transcriptional repression studies |
| Co-immunoprecipitation | Protein-protein interactions in TGF-beta2 pathway | Mechanistic studies |
RNA-seq and transcriptomics
RNA sequencing can quantify TGFB2 mRNA levels and identify transcriptional changes in response to negative regulators. This method is useful for discovering pathways that repress TGFB2 transcription.
Proteomics and ELISA
Measuring secreted TGF-beta2 protein by ELISA or mass spectrometry provides direct evidence of production regulation. Proteomics can also identify co-regulated proteins in the TGF-beta2 pathway.
CRISPR screens
Genome-wide CRISPR knockout or activation screens can identify genes whose loss or gain alters TGF-beta2 production. These screens are powerful for discovering novel negative regulators.
Functional assays
Assays such as collagen gel contraction, wound healing, and EMT marker expression can measure the downstream effects of altered TGF-beta2 production.
How CRISPR Can Be Used to Study GO:0032912 negative regulation of transforming growth factor beta2 production
Knockout
CRISPR knockout of TGFB2 or its negative regulators can reveal their causal role in production. For example, knocking out COL4A1 in corneal fibroblasts may increase TGF-beta2 production, confirming its feedback role. Knocking out ARG1 in lens epithelial cells can test its role in TGF-beta2-driven EMT.
Point Mutation
Introducing point mutations in SMAD4 or other pathway genes can mimic disease-associated variants and assess their impact on TGF-beta2 production and signaling. This is particularly useful for studying genetic susceptibility in asthma or cancer.
Knock-in
Knock-in of tagged TGFB2 (e.g., HA or GFP) allows tracking of endogenous TGF-beta2 production and secretion in real time. This can be combined with live-cell imaging to study dynamics.
Overexpression
Overexpression of negative regulators such as miR-483-3p or CD69 can reduce TGF-beta2 production and ameliorate disease phenotypes in cell models. This approach is useful for validating therapeutic candidates.
How EDITGENE Supports negative regulation of transforming growth factor beta2 production Research
Researchers studying negative regulation of transforming growth factor beta2 production-related genes often need to determine whether a candidate gene is causally involved in suppressing TGF-beta2 synthesis or secretion. EDITGENE provides comprehensive CRISPR-based services to enable such investigations, from knockout to precise point mutations and overexpression.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of transforming growth factor beta2 production research.
Frequently Asked Questions About negative regulation of transforming growth factor beta2 production
What is GO:0032912?
GO:0032912 is a Gene Ontology biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of production of transforming growth factor-beta2.
What genes are involved in negative regulation of TGF-beta2 production?
Key genes include TGFB2, SMAD4, MIR483, ARG1, CD69, IL10, COL4A1, SRC, and SNAI2, among others.
How is TGF-beta2 production negatively regulated?
It can be negatively regulated at transcriptional, post-transcriptional (e.g., by miR-483-3p), and feedback levels (e.g., by collagen type IV).
What diseases are associated with dysregulated TGF-beta2 production?
Diseases include corneal fibrosis, glaucoma, anterior subcapsular cataract, triple-negative breast cancer, asthma, and autoimmune conditions.
What experimental models are used to study this process?
Common models include CRISPR knockout cell lines, miRNA overexpression, point mutation knock-in, and animal models of fibrosis and cancer.
How can I measure TGF-beta2 production?
ELISA, Western blot, RNA-seq, and proteomics are standard methods to quantify TGF-beta2 mRNA and protein levels.
Is TGF-beta2 the same as TGF-beta1?
No, they are distinct isoforms encoded by different genes (TGFB2 and TGFB1) with overlapping but non-identical functions.
What is the role of miR-483-3p in TGF-beta2 regulation?
miR-483-3p targets the TGF-beta2/SMAD4 pathway and reduces extracellular matrix protein production in trabecular meshwork cells.
Can CRISPR be used to study negative regulation of TGF-beta2?
Yes, CRISPR knockout, knock-in, and overexpression are powerful tools to dissect the regulatory mechanisms.
What services does EDITGENE offer for TGF-beta2 research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services tailored to TGF-beta2 pathway studies.
Conclusion
GO:0032912, negative regulation of transforming growth factor beta2 production, is a critical biological process that controls the abundance of a potent cytokine involved in fibrosis, cancer, and immune regulation. Understanding its molecular mechanisms, from microRNA targeting to feedback inhibition, offers opportunities for therapeutic intervention. EDITGENE's CRISPR services empower researchers to dissect these pathways with precision and speed.
References
- 1. Sancho D et al.. 2003. CD69 downregulates autoimmune reactivity through active transforming growth factor-beta production in collagen-induced arthritis.. J Clin Invest 112(6):872-82 PMID: 12975472
- 2. Kuczynski EA et al.. 2011. Colorectal carcinoma cell production of transforming growth factor beta decreases expression of endothelial cell vascular endothelial growth factor receptor 2.. Cancer 117(24):5601-11 PMID: 21692070
- 3. Haribalaganesh R et al.. 2025. Hsa-MiR-483 -3p regulates the extracellular matrix proteins via TGFβ2/SMAD4 signaling in the glucocorticoid-responsive human trabecular meshwork cells.. Cell Tissue Res 401(2):145-154 PMID: 40471287
- 4. Angel CZ et al.. 2024. A SRC-slug-TGFβ2 signaling axis drives poor outcomes in triple-negative breast cancers.. Cell Commun Signal 22(1):454 PMID: 39327614
- 5. Wilson SE et al.. 2022. Corneal fibroblast collagen type IV negative feedback modulation of TGF beta: A fibrosis modulating system likely active in other organs.. Matrix Biol 109:162-172 PMID: 35421526
- 6. Bray P et al.. 1998. Transforming growth factor-beta and receptor tyrosine kinase-activating growth factors negatively regulate collagen genes in smooth muscle of hypertensive rats.. Hypertension 31(4):986-94 PMID: 9535425
- 7. Hobbs K et al.. 1998. Interleukin-10 and transforming growth factor-beta promoter polymorphisms in allergies and asthma.. Am J Respir Crit Care Med 158(6):1958-62 PMID: 9847292
- 8. Li Q et al.. 2023. Arginase-1 promotes lens epithelial-to-mesenchymal transition in different models of anterior subcapsular cataract.. Cell Commun Signal 21(1):236 PMID: 37723490
